[go: up one dir, main page]

DE68929151D1 - Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten - Google Patents

Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Info

Publication number
DE68929151D1
DE68929151D1 DE68929151T DE68929151T DE68929151D1 DE 68929151 D1 DE68929151 D1 DE 68929151D1 DE 68929151 T DE68929151 T DE 68929151T DE 68929151 T DE68929151 T DE 68929151T DE 68929151 D1 DE68929151 D1 DE 68929151D1
Authority
DE
Germany
Prior art keywords
polypeptide
amino acid
polypeptides
substituted
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929151T
Other languages
English (en)
Other versions
DE68929151T2 (de
Inventor
James A Wells
Brian C Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE68929151D1 publication Critical patent/DE68929151D1/de
Application granted granted Critical
Publication of DE68929151T2 publication Critical patent/DE68929151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DE68929151T 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten Expired - Lifetime DE68929151T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26461188A 1988-10-28 1988-10-28
US42806689A 1989-10-26 1989-10-26
PCT/US1989/004778 WO1990004788A1 (en) 1988-10-28 1989-10-30 Method for identifying active domains and amino acid residues in polypeptides and hormone variants

Publications (2)

Publication Number Publication Date
DE68929151D1 true DE68929151D1 (de) 2000-03-09
DE68929151T2 DE68929151T2 (de) 2000-07-20

Family

ID=26950658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68929151T Expired - Lifetime DE68929151T2 (de) 1988-10-28 1989-10-30 Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten

Country Status (6)

Country Link
US (4) US5580723A (de)
EP (1) EP0397834B1 (de)
AT (1) ATE189526T1 (de)
CA (2) CA2001774C (de)
DE (1) DE68929151T2 (de)
WO (1) WO1990004788A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0397834B1 (de) * 1988-10-28 2000-02-02 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US6583115B1 (en) * 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
CA2087267A1 (en) * 1990-08-17 1992-02-18 Steven H. Bass Metal ion mediated receptor binding of polypeptide hormones
NZ240718A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
US5310882A (en) * 1990-11-30 1994-05-10 American Cyanamid Company Somatotropins with alterations in the α-helix 3 region
EP0564531B1 (de) * 1990-12-03 1998-03-25 Genentech, Inc. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
JPH06504913A (ja) * 1991-01-17 1994-06-09 ザイモジェネティクス，インコーポレイティド グルカゴンアンタゴニストの検出方法
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
WO1992021029A1 (en) 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists
DK0642585T3 (da) * 1992-05-18 2006-05-15 Genentech Inc Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6335319B1 (en) * 1994-11-15 2002-01-01 Metabolic Pharmaceuticals, Inc. Treatment of obesity
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
PT1568772E (pt) * 1995-09-21 2010-04-14 Genentech Inc Variantes da hormona do crescimento humana
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6238915B1 (en) * 1996-02-13 2001-05-29 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
SE9601231D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Monoclonal antibody
US5945296A (en) 1996-03-29 1999-08-31 Pharmacia & Upjohn Ab Monoclonal antibody
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
ATE501170T1 (de) * 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK0973804T3 (da) * 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB9723955D0 (en) 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
GB2375765B (en) * 1997-11-14 2003-02-26 Kymed Gb Ltd Tagged growth hormone molecules
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
DE69940383D1 (de) 1998-10-21 2009-03-19 Chugai Pharmaceutical Co Ltd Verfahren zum screenen von verbindungen, die die produktion von entzündungszytokinen inhibieren
EP1141017B1 (de) 1998-12-30 2008-09-10 Beth Israel Deaconess Medical Center, Inc. Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
US7063959B1 (en) 1998-12-30 2006-06-20 Beth Israel Deaconess Medical Center, Inc. Compositions of the SOC/CRAC calcium channel protein family
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
JP2002537762A (ja) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US8153400B1 (en) 1999-04-26 2012-04-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids encoding a mutT domain-containing polypeptide
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001000874A2 (en) 1999-06-30 2001-01-04 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
JP2003516755A (ja) * 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
DE10016083A1 (de) * 2000-03-31 2001-10-18 Ingenium Pharmaceuticals Ag Nicht-menschliches Tiermodell für Wachstumsdefizienz und Defekte der Informationsverarbeitung oder der kognitiven Funktion und seine Verwendung
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
AU2001277014A1 (en) * 2000-07-21 2002-02-05 Trustees Of Boston University Modular vector systems
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
JP4520631B2 (ja) * 2000-11-22 2010-08-11 松本油脂製薬株式会社 耐久透水性付与剤及びその繊維
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
CA2460184A1 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP3425059A1 (de) 2002-05-09 2019-01-09 The Brigham and Women's Hospital, Inc. 1l1rl-1 als ein marker kardiovaskulärer krankheiten
WO2003102157A2 (en) * 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
EP1549740A2 (de) * 2002-07-30 2005-07-06 Stem Cell Therapeutics Inc. Oligodendrozytenherstellung aus multipotenten nervenstammzellen
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ATE425183T1 (de) 2002-10-07 2009-03-15 Ludwig Inst For Cancer Res Ltd P53-bindendes polypeptid
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7396646B2 (en) * 2003-01-22 2008-07-08 Modular Genetics, Inc. Alien sequences
US20050239082A1 (en) * 2003-01-22 2005-10-27 Temple Smith Alien sequences
MXPA05008533A (es) 2003-02-11 2005-10-20 Transkaryotic Therapies Inc Diagnostico y tratamiento de deficiencia de sulfatasa multiple y otras deficiencias de sulfatasa.
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
CA2553257A1 (en) 2004-01-14 2005-08-04 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
BRPI0506864A (pt) 2004-01-21 2007-05-29 Novo Nordisk As método para conjugar peptìdeos, peptìdeo conjugado, composto e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, composição farmacêutica, uso de um composto, e, método para tratamento de doença
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US7846898B2 (en) * 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1735336A2 (de) * 2004-04-16 2006-12-27 Genentech, Inc. Omi pdz-modulatoren
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
JP2008503233A (ja) * 2004-06-23 2008-02-07 ユーエスブイ・リミテッド 胎盤および下垂体アイソフォームに由来するキメラヒト成長ホルモンおよび該キメラを得るための方法
AU2005327906B2 (en) 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006073760A2 (en) 2004-12-17 2006-07-13 Dana-Farber Cancer Institute, Inc. Regulation of mink in thymocytes and t lymphocytes
EP1836298B1 (de) * 2004-12-22 2012-01-18 Ambrx, Inc. Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
BRPI0519430A2 (pt) * 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
CA2590462C (en) 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
JP2009509943A (ja) 2005-09-27 2009-03-12 ステム セル セラピューティクス コーポレイション プロラクチンにより制御される乏突起膠細胞前駆体細胞の増殖
EP2131195B1 (de) 2005-10-12 2012-04-25 Allergan, Inc. Tests der molekularen oder subzellulären Nähe unter Verwendung von Depolarisierung nach Resonanzenergietransfer (DARET)
EP2465870A1 (de) 2005-11-07 2012-06-20 Genentech, Inc. Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
CN106443006A (zh) * 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
EP1968635B1 (de) * 2005-12-14 2014-09-17 Ambrx, Inc. Zusammensetzungen und Verfahren mit und Verwendung von nicht-natürlichen Aminosäuren und Polypeptiden
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
EP2343551B1 (de) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ-Modulatoren
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CA2663083A1 (en) * 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
TW200823234A (en) * 2006-10-03 2008-06-01 Novo Nordisk As Peptides with high affinity for the prolactin receptor
CN103641908A (zh) 2007-03-22 2014-03-19 赫普泰雅治疗有限公司 突变的g蛋白偶联受体及其选择方法
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
AU2007353779B2 (en) * 2007-05-17 2013-11-07 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
NZ603812A (en) * 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
PL2318029T3 (pl) 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their applications
NO2337846T3 (de) * 2008-09-26 2018-06-16
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
SMT201700376T1 (it) 2009-06-05 2017-09-07 Ablynx Nv Costrutti trivalenti di nanobody anti-virus respiratorio sinciziale umano (hrsv) per la prevenzione e/o il trattamento di infezioni del tratto respiratorio
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
WO2011087808A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
CN106139158B (zh) 2010-01-22 2024-06-21 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
US20130143815A1 (en) 2010-07-22 2013-06-06 Novo Nordisk Health Care Ag Growth hormone conjugates
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
DK2605789T3 (da) 2010-08-17 2019-09-16 Ambrx Inc Modificerede relaxinpolypeptider og anvendelser deraf
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2446898A1 (de) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
US8623821B2 (en) 2011-10-14 2014-01-07 Genentech, Inc. Zymogen activators
CN106977587A (zh) 2011-10-14 2017-07-25 霍夫曼-拉罗奇有限公司 Bace1的肽抑制剂
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
KR20160019547A (ko) 2013-06-14 2016-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 안정화된 폴리펩티드 인슐린 수용체 조절제
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
EP3964522A1 (de) * 2015-11-16 2022-03-09 Ubiprotein, Corp. Verfahren zur verlängerung der halbwertszeit eines proteins
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
JP7372837B2 (ja) 2017-02-08 2023-11-01 ブリストル－マイヤーズ スクイブ カンパニー 薬物動態エンハンサーを含む修飾リラキシンポリペプチドおよびその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665160A (en) 1982-03-22 1987-05-12 Genentech, Inc. Novel human growth hormone like protein HGH-V encoded in the human genome
US4670393A (en) * 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4699897A (en) * 1983-06-04 1987-10-13 Amgen Biologically active peptides structurally related to regions within growth hormones
BG49718A3 (en) 1983-07-15 1992-01-15 Bio- Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4665180A (en) * 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
US4655160A (en) * 1985-09-10 1987-04-07 David R. Ligh Deck box
WO1988007084A1 (en) * 1987-03-12 1988-09-22 Amgen Inc. Bovine growth hormone analogs
EP0308499B1 (de) * 1987-04-02 1993-01-07 Genencor International, Inc. Substratunterstützte katalyse
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
EP0397834B1 (de) * 1988-10-28 2000-02-02 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6238915B1 (en) 1996-02-13 2001-05-29 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses

Also Published As

Publication number Publication date
US5580723A (en) 1996-12-03
DE68929151T2 (de) 2000-07-20
US5955346A (en) 1999-09-21
EP0397834B1 (de) 2000-02-02
EP0397834A1 (de) 1990-11-22
US6428954B1 (en) 2002-08-06
CA2001774C (en) 2001-10-16
CA2345497A1 (en) 1990-04-28
CA2001774A1 (en) 1990-04-28
WO1990004788A1 (en) 1990-05-03
ATE189526T1 (de) 2000-02-15
EP0397834A4 (en) 1992-10-28
US6451561B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
DE68929151D1 (de) Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
Lewis et al. Human growth hormone: a complex of proteins
Schally et al. The amino acid sequence of a peptide with growth hormone-releasing activity isolated from porcine hypothalamus
Hofmann et al. An approach to the targeted attachment of peptides and proteins to solid supports.
LU91015I2 (fr) Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
ATE87655T1 (de) Markierer der t-zelle aktivierung.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
Eipper et al. Amidation of joining peptide, a major pro-ACTH/endorphin-derived product peptide.
ES2090598T3 (es) Procedimiento de ensayo de proteinas de union de hormonas inmunofuncional mediado por ligando.
Sexton et al. Biologically active salmon calcitonin-like peptide is present in rat brain
Goltzman et al. Metabolism and biological activity of parathyroid hormone in renal cortical membranes.
Schwyzer Synthetische polypeptide mit physiologischer wirkung
Pickering et al. Adrenocorticotropins: XXIX. The action of sodium hydroxide on adrenocorticotropin
FERRARA et al. β‐ENDORPHIN: RADIORECEPTOR BINDING ASSAY: Relative Potency of Synthetic Analogs with Various Chain Lengths
Goltzman et al. Conversion of proparathyroid hormone to parathyroid hormone: studies in vitro with trypsin
Mallette Immunoreactivity of human parathyroid hormone (28-48): attempt to develop an assay for intact human parathyroid hormone
Vestling Insulin: HPLC mapping of protease digestion products: A biochemistry laboratory experiment
ATE180788T1 (de) Polypeptide mit einer aktivität des menschlichen dopaminergischen rezeptors, deren kodierende nukleinsäuresequenzen und verwendung dieser polypeptide
Nakagawa et al. Retro analogs related to oxytocin
Gargan et al. 206 The generation of a fibrin specific monoclonal antibody using a unique “antigen-free” animal system
Stötzer et al. 207 New methods for immunological determination of fibrin degradation products
Henschen et al. 205 Plasmic degradation of fibrinogen, fibrin and crosslinked fibrin, a comparison hy HPLC and sequence analysis
Knodrashina et al. Isolation and immunochemical characterization of soluble membrane proteins of the cell walls of diphtheria corynebacteria.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition